Results 191 to 200 of about 774,651 (293)

Ploidy‐dependent modulation of DNA replication kinetics in Xenopus

open access: yesThe FEBS Journal, EarlyView.
Using an interspecies replication system with Xenopus frog species of different ploidy levels, we investigated how DNA replication adapts to polyploidization. While replication was slower in tetraploid than in diploid nuclei, dodecaploid nuclei unexpectedly replicated faster than tetraploid nuclei. Our findings show that increasing genome size does not
Hemalatha Narassimprakash   +4 more
wiley   +1 more source

Elevated Creatine Kinase as a Marker for Aggressive GI Malignancy. [PDF]

open access: yesJ Community Hosp Intern Med Perspect
Vasireddy R   +3 more
europepmc   +1 more source

Energetic dysregulations in psychotic disorders: Targets for new therapeutics

open access: yesThe FEBS Journal, EarlyView.
The present review synthesizes literature documenting aberrant energy production and use, specifically related to mitochondrial and redox dysregulation, in psychotic disorders. Findings from different levels of investigation—genetic, cellular, and in vivo imaging—converge on aberrant energy metabolism as a hallmark of psychotic disorders.
Jacey Anderson   +10 more
wiley   +1 more source

Hydrothermal origin of metabolic phosphorylation

open access: yesThe FEBS Journal, EarlyView.
Serpentinizing hydrothermal vents are candidate sites for biochemical origins. They generate extremely reducing conditions, depositing phosphite (HPO32−) and transition metals, including palladium, in the native (zero‐valent) state. Schlikker et al.
Manon L. Schlikker   +5 more
wiley   +1 more source

Multi-ancestry genome-wide association study of serum creatine kinase implicates myopathy genes and muscle pathways. [PDF]

open access: yesEBioMedicine
Chen G   +7 more
europepmc   +1 more source

A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In moderate‐to‐severe plaque psoriasis, socrodeucitinib (6 mg/12 mg) significantly outperformed placebo at week 12: PASI 75 response rates 28.6%/72.1% vs. 7.5%. Meanwhile, socrodeucitinib illustrated a favourable safety and tolerability profile, warranting further study.
Ling Han   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy